LOS ANGELES, Jan 23 (Reuters) - Bristol-Myers Squibb Co and ImClone Systems, which last year was acquired by Eli Lilly and Co, said on Friday they will withdraw, and eventually resubmit, an application with U.S. regulators to market cancer drug Erbitux as a treatment for lung cancer.
